Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays therefor
AssigneeMigenix Inc.
InventorsChristen M. Anderson, Robert E. Davis, Tomas R. Szabo, Soumitra S. Ghosh, Walter H. Moos, Yazhong Pei
Life of this patent
Estimating the term…
Abstract
Compositions and methods are provided for producing adenine nucleotide translocator (ANT) polypeptides and fusion proteins, including the production and use of recombinant expression constructs having a regulated promoter. ANT ligands and compositions and methods for identifying ANT ligands, agents that bind ANT and agents that interact with ANT are also disclosed.
Claims11
A method for determining the presence of a human adenine nucleotide translocator (ANT) polypeptide in a biological sample comprising:
- contacting a biological sample suspected of containing a human ANT polypeptide with an ANT ligand under conditions and for a time sufficient to allow binding of the ANT ligand to a human ANT polypeptide;
- and
- detecting the binding of the ANT ligand to a human ANT polypeptide, and therefrom determining the presence of the human ANT polypeptide in said biological sample,
- wherein the ANT ligand comprises an atractyloside derivative having the following structure:
- and stereoisomers and pharmaceutically acceptable salts thereof,
- wherein
- R1 is halogen, —OC(═O)R4 or —NHR4;
- R2 is hydrogen or —C(═O)R5;
- R3 is —CH3 or ═CH2;
- R4 is —X-arylalkyl, —X-substituted arylalkyl, X-heteroaryl, or —X—heteroarylalkyl, wherein X is an optional amido or alkylamido linker moiety and
- R5 is alkyl.
A method for isolating a human adenine nucleotide translocator (ANT) polypeptide from a biological sample, comprising:
- contacting a biological sample suspected of containing a human ANT polypeptide with an ANT ligand under conditions and for a time sufficient to allow binding of the ANT ligand to the human ANT polypeptide;
- and
- recovering the human ANT polypeptide, and thereby isolating human ANT from a biological sample, wherein the ANT ligand comprises an atractyloside derivative having the following structure:
- and stereoisomers and pharmaceutically acceptable salts thereof,
- wherein
- R1 is halogen, —OC(═O)R4 or —NHR4;
- R2 is hydrogen or —C(═O)R5:
- R3 is —CH3 or ═CH2:
- R4 is —X—arylalkyl, —X—substituted arylalkyl, X—heteroaryl or —X—heteroarylalkyl, wherein X is an optional amido or alkylamido linker moiety;
- and
- R5 is alkyl.
Dependencies are inferred from the claim text.